Abstract
Monoclonal antibodies directed against proprotein convertase subtilisin–kexin type 9 (PCSK9) can reduce LDL cholesterol and lower cardiovascular risk
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
